AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33712965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilizarov ligamentotaxis
Number of subjects: 72
Study 33712965 — intervention group
Group type: COMPARATOR
Intervention: Locked volar plating
Number of subjects: 72
Study 33832957 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulberry twig alkaloids (SZ‐A)
Number of subjects: 600
Study 33832957 — intervention group
Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 600
Study 35028615 — intervention group
Group type: EXPERIMENTAL
Intervention: PXL770 500 mg QD
Number of subjects: 12
Study 35028615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 33236706 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with dual antiparasitic therapy and corticosteroids
Number of subjects: 0
Study 33236706 — intervention group
Group type: COMPARATOR
Intervention: Cysticidal therapy
Number of subjects: 0
Study 35594928 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon-only labels
Number of subjects: 1327
Study 35594928 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon-plus-text labels
Number of subjects: 1327
Study 35594928 — intervention group
Group type: COMPARATOR
Intervention: Control label
Number of subjects: 1327
Study 35594928 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1327
Study 34061558 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab, pembrolizumab plus axitinib, nivolumab plus cabozantinib, pembrolizumab plus lenvatinib
Number of subjects: 0
Study 34061558 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab and pembrolizumab
Number of subjects: 0
Study 34061558 — intervention group
Group type: COMPARATOR
Intervention: Enfortumab vedotin
Number of subjects: 0
Study 32877425 — intervention group
Group type: EXPERIMENTAL
Intervention: eQuoo app (gamified mobile mental health intervention)
Number of subjects: 358
Study 32877425 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy journal app (active control)
Number of subjects: 358
Study 32877425 — intervention group
Group type: COMPARATOR
Intervention: No-intervention waitlist (inactive control)
Number of subjects: 358
Study 34634832 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing (HW) for 30 seconds
Number of subjects: 14
Study 34634832 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-based sanitization for 30 seconds
Number of subjects: 14
Study 34703485 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender
Number of subjects: 97
Study 34703485 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with damask rose
Number of subjects: 97
Study 34703485 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine nursing care)
Number of subjects: 97
Study 35387431 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Drink (3 mg caffeine per kg of body weight)
Number of subjects: 27
Study 35387431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar amount of sugar without conventional ED ingredients)
Number of subjects: 27
Study 34602550 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (PALO)
Number of subjects: 267
Study 34602550 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (GRA)
Number of subjects: 267
Study 36231330 — intervention group
Group type: EXPERIMENTAL
Intervention: COLD
Number of subjects: 12
Study 36231330 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 12
Study 33892764 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced Aphasia Therapy Plus (CIAT Plus)
Number of subjects: 216
Study 33892764 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modality Aphasia Therapy (M-MAT)
Number of subjects: 216
Study 33892764 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 216
Study 33892764 — intervention group
Group type: EXPERIMENTAL
Intervention: CIAT Plus
Number of subjects: 216
Study 33892764 — intervention group
Group type: EXPERIMENTAL
Intervention: M-MAT
Number of subjects: 216
Study 33892764 — intervention group
Group type: EXPERIMENTAL
Intervention: CIAT Plus vs M-MAT
Number of subjects: 216
Study 32569239 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose of low‐molecular‐weight heparin sodium injection (FLUXUM)
Number of subjects: 307
Study 32569239 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of low‐molecular‐weight heparin sodium injection (FLUXUM)
Number of subjects: 307
Study 32569239 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban injection
Number of subjects: 307
Study 32569239 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 307
Study 34284646 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN) into the nodule of the MTrP
Number of subjects: 46
Study 34284646 — intervention group
Group type: COMPARATOR
Intervention: Dry needling (DN) into the taut band (TB) of the MTrP
Number of subjects: 46
Study 34316024 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Number of subjects: 25
Study 34316024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 35807800 — intervention group
Group type: EXPERIMENTAL
Intervention: Yerba Mate (YM) supplementation
Number of subjects: 10
Study 35807800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 34469262 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Interactive Training Sessions (BITS)
Number of subjects: 52
Study 34469262 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (Control)
Number of subjects: 52
Study 34904183 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-navigated microscope
Number of subjects: 55
Study 34904183 — intervention group
Group type: COMPARATOR
Intervention: Conventional neuronavigation
Number of subjects: 55
Study 34387274 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state responses of cortico-cortical evoked potentials (SSCCEPs)
Number of subjects: 11
Study 34387274 — intervention group
Group type: COMPARATOR
Intervention: Conventional cortico-cortical evoked potentials (CCEPs)
Number of subjects: 11
Study 34939824 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 42
Study 34939824 — intervention group
Group type: COMPARATOR
Intervention: Blood Glucose Meter (BGM)
Number of subjects: 42
Study 34851729 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 μg fentanyl
Number of subjects: 23
Study 32544459 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 35644684 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-iodine intake diet
Number of subjects: 37
Study 35644684 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg added to diet
Number of subjects: 37
Study 35644684 — intervention group
Group type: EXPERIMENTAL
Intervention: 125mL milk added to diet
Number of subjects: 37
Study 35644684 — intervention group
Group type: COMPARATOR
Intervention: Comparison of iodine intake and excretion increments
Number of subjects: 37
Study 35644684 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall iodine requirement evaluation
Number of subjects: 37
Study 33617161 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoelastic monoblock cup (RM Pressfit vitamys; Mathys)
Number of subjects: 50
Study 33617161 — intervention group
Group type: COMPARATOR
Intervention: Modular titanium cup (Allofit-S IT Alloclassic with a polyethylene liner; Zimmer)
Number of subjects: 50
Study 616766373 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication (Group B)
Number of subjects: 60
Study 616766373 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication and standardised preoperative information (Group C)
Number of subjects: 60
Study 616766373 — intervention group
Group type: COMPARATOR
Intervention: Standard pain management (Group A)
Number of subjects: 60
Study 35133631 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 196
Study 35133631 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 196
Study 33506195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sedation (lorazepam 1 mg/oxycodone 5 mg)
Number of subjects: 27
Study 33506195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 33719899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 19
Study 33719899 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 19
Study 34874654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin tablets, 2 tablets 2 times a day for 25 days
Number of subjects: 100
Study 34874654 — intervention group
Group type: COMPARATOR
Intervention: Other drugs (vitamins, nootropic drugs)
Number of subjects: 100
Study 34874654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 100
Study 36374982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordyceps cicadae mycelium supplementation (1,050 mg daily for 90 days)
Number of subjects: 70
Study 36374982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 32661006 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β‐1a (IFN β‐1a) administered at a dose of 44-μg/ml (12 million IU/ml) subcutaneously injected three times weekly for two consecutive weeks, in addition to national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir)
Number of subjects: 92
Study 32661006 — intervention group
Group type: COMPARATOR
Intervention: Control group received only national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir)
Number of subjects: 92
Study 33485340 — intervention group
Group type: EXPERIMENTAL
Intervention: PA enabling uniform (shorts, polo shirt, sports shoes)
Number of subjects: 2180
Study 33485340 — intervention group
Group type: COMPARATOR
Intervention: Usual traditional uniform
Number of subjects: 2180
Study 32390248 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone (150 mg TID)
Number of subjects: 0
Study 32390248 — intervention group
Group type: COMPARATOR
Intervention: Cyclobenzaprine (10 mg TID)
Number of subjects: 0
Study 32390248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35759108 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive trans-spinal magnetic stimulation (rTSMS)
Number of subjects: 100
Study 35759108 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 100
Study 33078467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) - Group format
Number of subjects: 268
Study 33078467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) - Individual format
Number of subjects: 268
Study 33078467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) - Both formats (Group and Individual)
Number of subjects: 268
Study 35694708 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-made Hewei decoction plus conventional western medicine
Number of subjects: 166
Study 35694708 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine
Number of subjects: 166
Study 34301974 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram for 7 days
Number of subjects: 60
Study 34301974 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 60
Study 32279888 — intervention group
Group type: EXPERIMENTAL
Intervention: Reso‐Pac® dressing
Number of subjects: 100
Study 32279888 — intervention group
Group type: COMPARATOR
Intervention: Control (no dressing)
Number of subjects: 100
Study 36349334 — intervention group
Group type: EXPERIMENTAL
Intervention: BASPLA
Number of subjects: 120
Study 36349334 — intervention group
Group type: COMPARATOR
Intervention: CLA
Number of subjects: 120
Study 33777423 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing and telehealth awareness
Number of subjects: 523
Study 33777423 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attitude towards telenursing and telehealth
Number of subjects: 523
Study 33777423 — intervention group
Group type: COMPARATOR
Intervention: Telehealth awareness by education level
Number of subjects: 523
Study 33777423 — intervention group
Group type: COMPARATOR
Intervention: Positive attitude towards telehealth and telenursing by profession
Number of subjects: 523
Study 34898083 — intervention group
Group type: EXPERIMENTAL
Intervention: One-glass test
Number of subjects: 360
Study 34898083 — intervention group
Group type: COMPARATOR
Intervention: Four-glass test
Number of subjects: 360
Study 35644305 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-4379 10 mg QD
Number of subjects: 48
Study 35644305 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-4379 30 mg QD
Number of subjects: 48
Study 35644305 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-4379 40 mg BID
Number of subjects: 48
Study 35644305 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-4379 80 mg QD
Number of subjects: 48
Study 35644305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 35644305 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-4379
Number of subjects: 48
Study 32250534 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6 to 1.8 mg over 24 weeks)
Number of subjects: 15
Study 32250534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 34304419 — intervention group
Group type: EXPERIMENTAL
Intervention: MR and JVE‐L combined vaccination group (experimental group)
Number of subjects: 0
Study 34304419 — intervention group
Group type: COMPARATOR
Intervention: MR single vaccination group (control group)
Number of subjects: 0
Study 33040011 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Fixation (IF)
Number of subjects: 0
Study 33040011 — intervention group
Group type: COMPARATOR
Intervention: Arthroplasty
Number of subjects: 0
Study 36453305 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling Motivational Card (SMC)
Number of subjects: 234
Study 36453305 — intervention group
Group type: COMPARATOR
Intervention: Oral counseling
Number of subjects: 234
Study 36453305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 234
Study 33765257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-directed home blood pressure monitoring (HBPM)
Number of subjects: 126
Study 33765257 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study 32610487 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strategies
Number of subjects: 69
Study 32610487 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity strategies
Number of subjects: 69
Study 32610487 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 69
Study 34957621 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Literacy Education (HL-AE)
Number of subjects: 182
Study 34957621 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal Education (AE)
Number of subjects: 182
Study 34957621 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 182
Study 32651768 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic epinephrine (RE) nebulization, 0.2 ml of RE added to 1.8 ml of distilled water, re-administered if needed on 6 h.
Number of subjects: 80
Study 32651768 — intervention group
Group type: COMPARATOR
Intervention: 3% hypertonic saline (HS) nebulization, 2 ml of 3% HS nebulized, frequency of 1 to 4 h.
Number of subjects: 80
Study 35289756 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered eHealth intervention (telephone support and web-based platform)
Number of subjects: 209
Study 35289756 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 209
Study 35018614 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (participants moved a virtual paddle to bounce target objects)
Number of subjects: 0
Study 35018614 — intervention group
Group type: COMPARATOR
Intervention: Passive group (participants viewed recordings of trials from the active groups)
Number of subjects: 0
Study 33199044 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted plasma phospholipid AA concentrations
Number of subjects: 367643
Study 32336236 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 15245
Study 32336236 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 15245
Study 33662615 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold nanosecond laser (SNL) treatment
Number of subjects: 212
Study 33662615 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 212
Study 33662615 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of SNL vs sham
Number of subjects: 212
Study 34670994 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and Pain Management Program (12 sessions, 90 minutes each, plus supervised exercise 3 times per week)
Number of subjects: 50
Study 34670994 — intervention group
Group type: COMPARATOR
Intervention: Standard care of RA
Number of subjects: 50
Study 33075621 — intervention group
Group type: EXPERIMENTAL
Intervention: DA preload and rice (PDA + R)
Number of subjects: 15
Study 33075621 — intervention group
Group type: EXPERIMENTAL
Intervention: rice with sugar solution (PSS + R)
Number of subjects: 15
Study 33075621 — intervention group
Group type: EXPERIMENTAL
Intervention: co-ingestion of rice with vinegar-soaked DA (VDA + R)
Number of subjects: 15
Study 33075621 — intervention group
Group type: COMPARATOR
Intervention: rice (reference)
Number of subjects: 15
Study 36271471 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon PTH (18 μg/d)
Number of subjects: 84
Study 36271471 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon PTH
Number of subjects: 84
Study 36271471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 33658612 — intervention group
Group type: EXPERIMENTAL
Intervention: Drone landed on abdomen
Number of subjects: 46
Study 33658612 — intervention group
Group type: EXPERIMENTAL
Intervention: Drone hovering over participants in supine position
Number of subjects: 46
Study 33658612 — intervention group
Group type: EXPERIMENTAL
Intervention: Drone landed on abdomen in prone position
Number of subjects: 46
Study 33658612 — intervention group
Group type: EXPERIMENTAL
Intervention: Drone hovering over participants in prone position
Number of subjects: 46
Study 32487594 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy intervention
Number of subjects: 634
Study 32487594 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 634
Study 32487594 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (both health literacy and exercise)
Number of subjects: 634
Study 32487594 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 634
Study 35353415 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week school-based mindfulness intervention
Number of subjects: 369
Study 35353415 — intervention group
Group type: COMPARATOR
Intervention: Active control group receiving relaxation program
Number of subjects: 369
Study 35353415 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 369
Study 33794354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 0
Study 33794354 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT + Contingency Management (CM)
Number of subjects: 0
Study 33794354 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch medications from NRT to varenicline
Number of subjects: 0
Study 33794354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensify treatment to a higher CM reward schedule
Number of subjects: 0
Study 32245170 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal 25-hydroxyvitamin D3 (25(OH)D3) concentrations, specifically in the fifth quintile
Number of subjects: 1423
Study 32245170 — intervention group
Group type: COMPARATOR
Intervention: First quintile of neonatal 25-hydroxyvitamin D3 (25(OH)D3) concentrations
Number of subjects: 1423
Study 35780589 — intervention group
Group type: EXPERIMENTAL
Intervention: QLC (Qilong capsule) combined with conventional treatment (CT)
Number of subjects: 2302
Study 35780589 — intervention group
Group type: COMPARATOR
Intervention: CT alone (non-QLC group)
Number of subjects: 2302
Study 33667304 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% inspired oxygen
Number of subjects: 2801
Study 33667304 — intervention group
Group type: COMPARATOR
Intervention: 30% inspired oxygen
Number of subjects: 2801
Study 33418612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic hip screw with anti-rotation screw
Number of subjects: 364
Study 33418612 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw
Number of subjects: 364
Study 34728131 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant and concurrent androgen deprivation therapy (ADT) for 6 months starting 4 months before prostate radiotherapy
Number of subjects: 393
Study 34728131 — intervention group
Group type: COMPARATOR
Intervention: Concurrent and adjuvant ADT for 6 months starting simultaneously with prostate radiotherapy
Number of subjects: 393
Study 34130902 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective morning chronotype
Number of subjects: 0
Study 34130902 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective-measured morning chronotype
Number of subjects: 0
Study 34130902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep efficiency
Number of subjects: 0
Study 34130902 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 0
Study 35152129 — intervention group
Group type: EXPERIMENTAL
Intervention: Early NIHSS assessment
Number of subjects: 372
Study 35152129 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of NIHSS increase with ICH volume
Number of subjects: 372
Study 32796442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant injection
Number of subjects: 42
Study 35807864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol treatment
Number of subjects: 10
Study 35807864 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study 35807864 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol treatment (in vitro)
Number of subjects: 10